A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objective The long-acting glucagon-like peptide 1 receptor agonist liraglutide is linked to progressive and sustained weight loss in obese people with diabetes. However, its efficacy and safety in women with polycystic ovary syndrome (PCOS) has not yet been addressed.Design Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin). The main outcome was change in body weight.Results Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups. However, in a subgroup of patients (n=9) with insulin resistance (HOMA(IR) >2), severe obesity and higher odds ratio for the metabolic syndrome (OR=3.9), the patients fared much better with liraglutide than with metformin (mean BMI decreased 2.13 kg/m(2) vs. 0.62 kg/m(2), respectively).Conclusions Short-term liraglutide treatment was associated with significant weight loss in a subset of obese patients with newly diagnosed PCOS and a higher metabolic risk profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the same Authors in the second study, failed to demonstrate a reduction in HOMA-IR, fasting glucose and insulin and glucose and insulin during OGTT in both treated groups [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“the authors reported a significant reduction of total testosterone and LH in only metformin group, while treatment with liraglutide led to a significant LH increase, without differences in FG score between the two groups [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“However, in the subgroup of patients with insulin resistance, severe obesity and higher odds ratio for the metabolic syndrome, BMI decreased more with liraglutide than with metformin (2.13 kg/m2 vs. 0.62 kg/m2, respectively)”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“Comparing the efficacy of liraglutide 1.2 mg/day vs metformin 1000 mg BID (twice daily), Jensterle et al. carried out two 12-week studies offering different results: the first study showed that liraglutide was superior to metformin in reducing body weight, BMI, and WC [57], while in the second study, both the treatments proved to be equally effective with no differences between the groups [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
In the citing paper
“suggesting a greater effect of liraglutide in subjects with insulin resistance and higher metabolic risk profile [58].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Research works printed but not linked: 1
- American Diabetes Association, 2013 Standards of Medical Care in Diabetes-2013. Diabetes Care 36: Suppl 1: 26–27.
Cited by
Items 101–117 of 117
SINDROME DE RAPUNZEL: TRICOBEZOAR GASTRODUODENAL GIGANTE
MEDEIROS, A. A. D. A., & Magalhães, A. W. D. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004918
BENEFÍCIOS DA AURICULOTERAPIA EM PACIENTES COM DORES CRÔNICAS
Cavalcante, F. V., Mendes, M. R. P., & Ferreira, P. D. D. S. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004817
Aguiar, G. E. D., Nani, M. C. B., Bani, G. M. A. C., & Nasser, T. F. (2021) · Editora Conhecimento Livre eBooks · doi:10.37423/211004906
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Abdulrahman, A. J., AL-Zobaidy, M. A.-H. J., & Najjar, S. A. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.266014
Hossain, A., Banu, H., Morshed, M. S., & Afrine, S. (2023) · IMC Journal of Medical Science · doi:10.55010/imcjms.18.002 · Cited by 2
A eficácia da liraglutida no tratamento da obesidade - uma revisão integrativa
Fonseca, I. F., Borges, G. D., Gonçalves, G. C., Moreira, F. P., & de Siqueira, E. C. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-057
Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
Jaroń, A., Wiklińska, A., Jastrzębska, K., Witkowska, M., Skotnicka, J., Błaszczak, K., Turek, M., Wojciechowska, K., Borkowski, A., & Sawicki, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53831 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists' Effect on Polycystic Ovary Syndrome: A Meta Analysis
Li, X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.19862
Son, J., Shin, S., Kim, J., Kang, M., Lee, D., Jeon, S., Kim, J., Kim, C., Kang, B., & Bang, M. (2025) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2025.25.1.17
Current Available Pharmacological Intervention for PCOS-II
Baba, M. S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810962125010006 · Cited by 1
Zhou, L., Qu, H., Yang, L., & Shou, L. (2024) · Figshare · doi:10.6084/m9.figshare.26637207
Mularczyk, P., Polek, N., Sikorska, M., Łysoniewski, W., Marcysiak, A., Mruzek, T., Kiełbasiewicz, M., & Zawadzka, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5668
“• A significant decrease in waist circumference and in visceral adipose tissue (VAT) area as measured by DXA (p = 0.015) (M. Jensterle et al., 2015).”
InfluentialBanerjee, I., Krissheeven, M., Pandey, N., Banerjee, S., Robinson, J., & Banerjee, I. (2026) · Cureus · doi:10.7759/cureus.115758 · Cited by 2
“Seven RCTs were finally assessed and were, hence, included for quantitative synthesis for systematic review and meta-analysis [17-23].”
InfluentialGenetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity
Fernandes, M. T., Dias, J. C., Espírito‐Santo, M., Estêvão, M. D., & Sousa‐Coelho, A. L. D. (2026) · Life · doi:10.3390/life16091486
“Carriers of at least one rs10305420 T allele had a lower likelihood of being classified as strong responders than carriers of two C alleles [32].”
InfluentialOBESITY, ENDOMETRIOSIS, AND GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW
Wróblewska, O., Majewski, J., Witaszczyk, M., Hałabuda, Z., Jędryka, M., Paczyna, J., Benecka, A., & Kawka-Bryk, I. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6411
Kawuribi, V., Adu‐Amankwaah, J., & Yalley, S. K. (2026) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2026.106034
Metadata
- Authors
- Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A.
- Affiliations
- Ljubljana University Medical Centre (SI)
- Venue
- Hormones
- Published
- 2015-01
- Volume
- 14
- Issue
- 1
- Pages
- 81-90
- ISSN
- 1109-3099 (ISSN-L)
- 2520-8721
- OpenAlex
- W2330618995
- Cited by
- 117
- References
- 39
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 8 · 2022: 18 · 2021: 17 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 4
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- HORMONES (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- liraglutide, polycystic ovary syndrome, obesity, weight loss, GLP-1 receptor agonists, metformin, insulin resistance, metabolic syndrome, body mass index, waist circumference, fat mass
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Metformin, Obesity, Polycystic Ovary Syndrome, Weight Loss, Body Mass Index, Treatment Outcome, Incretins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.